Polyoxazoline Matrix Sustained Release High Drug Load

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current polymers fail to achieve sustained release of highly soluble active pharmaceutical ingredients beyond 40% drug load, leading to fluctuations in plasma drug concentrations and inefficient therapy due to rapid drug release or burst release issues in oral solid dosage forms.

Innovation Solution

Development of polymer combinations comprising poly(2-oxazoline)s, specifically blends with at least 25% poly(2-C3-5-alkyl-2-oxazoline)s, which are used in combination with active pharmaceutical ingredients to create sustained release formulations that control the release of hydrophilic drugs over an extended period.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If conventional polymers (HPMC, ethylcellulose) are used for sustained release formulations, then the formulations can be manufactured with straightforward processing, but the drug release is too fast and shows burst release when drug loading exceeds 40% (w/w)

Engineering Contradiction:

Improveprocessing straightforwardnessVSAvoidsustained release capability

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent uses composite materials by combining polyoxazoline polymers with other polymers or materials to create a sustained release formulation that maintains drug release control at high drug loadings (up to 80% w/w), overcoming the limitations of single conventional polymers like HPMC that fail to provide sustained release above 40% drug loading

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent applies parameter changes by modifying the polymer structure (using polyoxazolines with specific molecular weights and compositions) and formulation parameters (drug:polymer ratios, processing conditions) to achieve sustained release at high drug loadings while maintaining manufacturability through direct compression or wet granulation

Inventive Principle:

Principle #35Parameter changes

2Reliability

If maximum 40% (w/w) drug loading is used in sustained release formulations, then sustained drug release over 24 hours can be achieved, but the therapeutic window is limited and multiple administrations are required

Engineering Contradiction:

Improvesustained release durationVSAvoiddrug loading capacity

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent achieves high drug loading (up to 80% w/w) while maintaining sustained release by changing key parameters including using polyoxazoline polymers with specific molecular weights (10,000-500,000 g/mol), optimizing the drug:polymer ratio, and adjusting processing parameters to control drug release kinetics at high concentrations

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The formulation uses composite material systems combining polyoxazoline polymers with active pharmaceutical ingredients at high ratios, creating a matrix that maintains structural integrity and controlled release properties even at 80% w/w drug loading, thereby extending the therapeutic duration

Inventive Principle:

Principle #40Composite materials

3Productivity

If periodic drug administration is used to maintain therapeutic levels, then the dosage can be adjusted, but plasma concentration fluctuations cause toxic and sub-therapeutic levels

Engineering Contradiction:

Improvedosage flexibilityVSAvoidplasma concentration fluctuation

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The sustained release formulation provides continuous drug release over 24 hours or longer, maintaining steady plasma concentrations within the therapeutic window and eliminating the fluctuations that cause toxic or sub-therapeutic levels associated with periodic administration

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The polyoxazoline polymer matrix acts as an intermediary that controls and modulates drug release, providing a buffer that maintains stable plasma concentrations by releasing drug gradually rather than in periodic pulses

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The polymer combinations effectively manage the release of active ingredients, ensuring between 10-80% of the drug is released within the first 6-24 hours, with no more than 75% released in the first 120 minutes, thereby maintaining therapeutic plasma levels and improving patient compliance.

Implementation Method 1

the drug release of formulations including maximum 40% (w/w) of drug load can be sustained over 24 h

Methodology Applied

Scientific EffectDiffusion: Diffusion

Implementation Method 2

Hydroxypropylmethylcellulose (HPMC) is currently by far the most commonly used polymer for sustained release as it allows relatively high drug loadings

Methodology Applied

Scientific EffectErosion:

Data Source

PatentUS12251443B2Drug formulations comprising polyoxazolines as matrix excipient

Publication Date: 2025.03.18 UNIV GENT

AI summary

Polyoxazoline polymers, polymer combinations, and compositions comprising those polymers or combinations of polymers are disclosed. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.